Stocks Health care KYTX
NASDAQ · Health careKyverna Therapeutics, Inc. (KYTX)
It posted a net loss of $152.6M. In fiscal 2025 capital spending exceeded operating cash flow by $153.7M. At June 30, 2026 it held $31.8M in cash against $24.9M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Key facts about Kyverna Therapeutics, Inc.
- Net worth
- Kyverna Therapeutics, Inc. has a market value (market cap) of $314.2M at the latest share price, and shareholders' equity of $165.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $153.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Kyverna Therapeutics, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Kyverna Therapeutics, Inc. does
Kyverna Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker KYTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$161.3M | -$3.64 | -$153.7M |
| 2024 | n/a | -$127.5M | -$3.33 | -$116.5M |
| 2024 | n/a | -$60.4M | -$89.61 | -$53M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Kyverna Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 19, 2026Passive stake (5% or more) SCHEDULE 13G
- September 24, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026
- August 11, 2026
- July 29, 2026Passive stake (5% or more) SCHEDULE 13G
- July 27, 2026
- July 9, 2026
- June 2, 2026
- May 18, 2026
Insider trades
What the people running Kyverna Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 27, 2026 | Aktar MertDirector | Received as pay | 5,093 | - |
| May 27, 2026 | Shaw ChristiExecutive Chairperson, Director | Shares withheld for tax | 4,194 | $36K |
| May 27, 2026 | Seidenberg Beth CDirector | Received as pay | 5,093 | - |
| May 27, 2026 | Cohen Fred EDirector | Received as pay | 5,093 | - |
| May 27, 2026 | Clark Ian TDirector | Received as pay | 5,093 | - |
| March 13, 2026 | Biddle Warner WestonChief Executive Officer, Director | Received as pay | 58,000 | - |
| March 13, 2026 | Grasso MarcChief Financial Officer | Received as pay | 10,000 | - |
| March 13, 2026 | Gehchan NajiSee Remarks | Received as pay | 18,000 | - |
Who owns KYTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vida Ventures, LLC13D, may seek influence with 5 related filers | 11.1% | May 3, 2024 |
| Westlake BioPartners Fund I, L.P. ("Westlake Fund I")13G, passive with 1 related filers | 8.8% | November 12, 2024 |
| Dr. Beth C. Seidenberg ("Seidenberg")13G, passive with 4 related filers | 7.8% | February 6, 2026 |
| GordonMD Global Investments LP13G, passive with 4 related filers | 7% | November 17, 2025 |
| Michael P. Rubin13G, passive with 6 related filers | 6.1% | February 17, 2026 |
| Orin Hirschman13G, passive with 1 related filers | 5.9% | October 19, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 120 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| GordonMD Global Investments LP | 4,244,818 | 0 |
| Gilead Sciences, Inc. | 4,126,119 | 0 |
| BlackRock, Inc. | 3,134,807 | +2,257,729 |
| Bain Capital Life Sciences Investors, LLC | 2,885,000 | -225,000 |
| AIGH Capital Management LLC | 2,795,797 | +795,797 |
| Deerfield Management Company, L.P. | 2,000,000 | 0 |
| Vanguard Capital Management LLC | 1,897,451 | +114,109 |
| Geode Capital Management, LLC | 1,049,430 | +625,604 |
| Insight Holdings Group, LLC | 989,054 | 0 |
| Morgan Stanley | 982,307 | +5,018 |
| State Street Corp | 982,233 | +843,933 |
| Propel Bio Management, LLC | 883,198 | +238,777 |
| Woodline Partners LP | 845,325 | 0 |
| Millennium Management LLC | 639,780 | -365,728 |
| Mbb Public Markets I LLC | 614,477 | 0 |
| Adage Capital Partners GP, L.L.C. | 500,000 | 0 |
| D. E. Shaw & Co., Inc. | 469,346 | -252,235 |
| Wells Fargo & Company | 373,009 | +258,610 |
| UBS Group AG | 365,574 | -84,176 |
| Goldman Sachs Group Inc | 335,230 | +122,320 |
Insiders
12 insiders reported holding 2,022,931 shares in total, about $10.3M at the last price.
| Holder | Shares |
|---|---|
| Seidenberg Beth CDirector | 891,044869,317 held indirectly |
| Westlake BioPartners Opportunity Fund I, L.P.10% owner | 869,317869,317 held indirectly |
| Shaw ChristiExecutive Chairperson, Director | 66,741 |
| Biddle Warner WestonChief Executive Officer, Director | 58,000 |
| Walker Karen MarieChief Technology Officer | 22,636 |
| Cohen Fred EDirector | 21,727 |
| Aktar MertDirector | 21,727 |
| Clark Ian TDirector | 21,727 |
| Gehchan NajiSee Remarks | 18,000 |
| Emany Sravan KumarDirector | 11,006 |
Questions about KYTX
What does Kyverna Therapeutics, Inc. do?
Kyverna Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as KYTX. Its shares trade on NASDAQ under the ticker KYTX.
What is Kyverna Therapeutics, Inc.'s net worth?
Kyverna Therapeutics, Inc. has a market value (market cap) of $314.2M at the latest share price, and shareholders' equity of $165.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Kyverna Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $152.6M.
When did Kyverna Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from October 19, 2026.
When is Kyverna Therapeutics, Inc.'s next earnings report?
Kyverna Therapeutics, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare KYTX with
Follow KYTX
Get an email when Kyverna Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Kyverna Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.